{"id":55242,"date":"2023-03-28T11:05:51","date_gmt":"2023-03-28T09:05:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/"},"modified":"2023-03-28T11:05:51","modified_gmt":"2023-03-28T09:05:51","slug":"salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/","title":{"rendered":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates"},"content":{"rendered":"
\n

\n\u2013 <\/i>JK07 Advancing into Phase 2 Clinical Trial in <\/i>Heart Failure with Reduced Ejection Fraction (HFrEF);<\/i> Topline Phase 1b Results Expected in 1H 2023 <\/i>\u2013<\/i>\n<\/p>\n

\n\u2013Fourth Cohort Enrolling in Phase 1\/2 Study Evaluating JK08 Monotherapy in Advanced Solid Tumors; Favorable Pharmacodynamic Activities Observed Across Cohorts<\/i> <\/i>\u2013<\/i>\n<\/p>\n

GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced it received $35 million in financing from China-based Shenzhen Salubris Pharmaceuticals Co., Ltd. The investment will be used to advance and accelerate lead candidate JK07, including the planned initiation of the first Phase 2 study in HFrEF, the continuation of the ongoing Phase 1b clinical trial in heart failure with preserved ejection fraction (HFpEF), and the launch of the Company\u2019s first neurology clinical trial with JK07. The financing will also support the ongoing Phase 1\/2 trial of JK08 in solid tumors and advance JK06, a pre-clinical biparatopic antibody-drug conjugate, into an initial Phase 1\/2 study.\n<\/p>\n

<\/a><\/p>\n

\n\u201cWe\u2019re thrilled about the progress we made in 2022, particularly completing enrollment in the Phase 1b study of JK07 in HFrEF. The study achieved its objective of characterizing the safety and activity of the molecule and defining the therapeutic window. We\u2019re excited to now turn our focus towards initiating a Phase 2 study this year,\u201d said Sam Murphy, Chief Executive Officer of SalubrisBio. \u201cWe look forward to multiple additional milestones across our pipeline in the year ahead, including interim data readouts from JK07 in HFpEF and JK08 in solid tumors, and initiation of an initial clinical trial evaluating JK07 in neurodegenerative disease.\u201d\n<\/p>\n

\nJK07 Advancing into Phase 2<\/b>\n<\/p>\n

\nPatient dosing has been completed in the Phase 1b clinical trial assessing the safety, tolerability, pharmacokinetics and exploratory efficacy of JK07 in HFrEF. This study demonstrated robust changes in biomarkers and exploratory efficacy parameters at dose levels that were safe and well tolerated. Topline results are planned to be presented at an upcoming medical meeting. The first Phase 2 study is expected to begin in 2H of 2023. A second Phase 1b study in HFpEF is actively enrolling, with interim results expected in the second half of 2023.\n<\/p>\n

\nFor more information on the JK07 clinical trial, please visit https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04210375<\/a> and https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05322616<\/a>.\n<\/p>\n

\nJK08 Phase 1\/2 Study Progress<\/b>\n<\/p>\n

\nThe fourth cohort in the ongoing Phase 1\/2 study of JK08 as a monotherapy treatment for solid tumors is now recruiting. Through the first three cohorts, preliminary data indicate favorable safety and encouraging, dose-dependent pharmacodynamic activity. SalubrisBio expects to report preliminary findings later this year at a medical meeting.\n<\/p>\n

\nFor more information on the JK08 clinical trial, please visit https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05620134<\/a>.\n<\/p>\n

\nAbout JK07<\/b>\n<\/p>\n

\nJK07 is a recombinant fusion protein consisting of a fully human immunoglobulin IgG1 monoclonal antibody and an active polypeptide fragment of the human growth factor neuregulin [NRG-1]. NRG-1 is a clinically validated growth factor that has shown promising activity in HFrEF, but also undesirable side effects. Research has shown that NRG-1 induces signaling through interaction with two different receptors \u2013 HER3\/ErbB3 and HER4\/ErbB4. The HER4\/ErbB4 pathway appears to be responsible for the regenerative effects in the heart, while the HER3\/ErbB3 pathway appears primarily responsible for safety and tolerability limitations of recombinant NRG-1. By blocking HER3\/ErbB3 signaling with an antibody fusion design, JK07 selectively stimulates the HER4\/ErbB4 pathway with a favorable pharmacokinetic profile, which has the potential to significantly widen the therapeutic window of NRG-1 and yield better clinical effects.\n<\/p>\n

\nAbout JK08<\/b>\n<\/p>\n

\nJK08 is a recombinant fusion protein consisting of a CTLA-4-specific antibody and a C-terminal IL-15\/sushi domain. JK08 was designed based on clinical studies from both individual molecules, which together portend synergistic effects in an antibody fusion construct. The CTLA-4-specific antibody ipilimumab validated CTLA-4 as a target for cancer therapy, but response rates are limited. Analysis of clinical samples demonstrated that NK cell activity signatures and ADCC biomarkers correlate with ipilimumab responses. Recombinant IL-15 has demonstrated potent stimulation of NK cell expansion and activation in clinical studies. JK08 channels the potent immune stimulation of IL-15 through the CTLA-4 antibody domain towards T-regulatory cell depletion and reversing immunosuppression which may contribute to cancer progression.\n<\/p>\n

\nAbout SalubrisBio<\/strong>\n<\/p>\n

\nSalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases. SalubrisBio was founded in August 2016 as a wholly-owned subsidiary of the China-based pharmaceutical company Shenzhen Salubris Pharmaceuticals Co. Ltd. Headquartered in the US, SalubrisBio reflects Shenzhen Salubris Pharmaceuticals\u2019 commitment to innovation and expansion into the global market and retains the core philosophy of developing therapeutics for large patient populations with significant unmet needs.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor further information, please contact:<\/b>
Argot Partners
\n
212.600.1902|SalubrisBio@argotpartners.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 JK07 Advancing into Phase 2 Clinical Trial in Heart Failure with Reduced Ejection Fraction (HFrEF); Topline Phase 1b Results Expected in 1H 2023 \u2013 \u2013Fourth Cohort Enrolling in Phase 1\/2 Study Evaluating JK08 Monotherapy in Advanced Solid Tumors; Favorable Pharmacodynamic Activities Observed Across Cohorts \u2013 GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-55242","format-standard","category-industry"],"yoast_head":"\nSalubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 JK07 Advancing into Phase 2 Clinical Trial in Heart Failure with Reduced Ejection Fraction (HFrEF); Topline Phase 1b Results Expected in 1H 2023 \u2013 \u2013Fourth Cohort Enrolling in Phase 1\/2 Study Evaluating JK08 Monotherapy in Advanced Solid Tumors; Favorable Pharmacodynamic Activities Observed Across Cohorts \u2013 GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T09:05:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230328005061\/en\/1747213\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates\",\"datePublished\":\"2023-03-28T09:05:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/\"},\"wordCount\":790,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005061\\\/en\\\/1747213\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/\",\"name\":\"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005061\\\/en\\\/1747213\\\/21\\\/Logo.jpg\",\"datePublished\":\"2023-03-28T09:05:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005061\\\/en\\\/1747213\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005061\\\/en\\\/1747213\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/","og_locale":"en_US","og_type":"article","og_title":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates - Pharma Trend","og_description":"\u2013 JK07 Advancing into Phase 2 Clinical Trial in Heart Failure with Reduced Ejection Fraction (HFrEF); Topline Phase 1b Results Expected in 1H 2023 \u2013 \u2013Fourth Cohort Enrolling in Phase 1\/2 Study Evaluating JK08 Monotherapy in Advanced Solid Tumors; Favorable Pharmacodynamic Activities Observed Across Cohorts \u2013 GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-28T09:05:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230328005061\/en\/1747213\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates","datePublished":"2023-03-28T09:05:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/"},"wordCount":790,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005061\/en\/1747213\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/","url":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/","name":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005061\/en\/1747213\/21\/Logo.jpg","datePublished":"2023-03-28T09:05:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230328005061\/en\/1747213\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230328005061\/en\/1747213\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55242"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55242\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}